---
{"dg-publish":true,"permalink":"/ğŸ“ç ”ç©¶ç”Ÿ/ğŸŒ™fNIRS+PTSD/æ–‡çŒ®é˜…è¯»/A Functional Near-Infrared Spectroscopy Study of Trauma-Related Auditory and Olfactory Cues - Posttraumatic Stress Disorder or Combat Experience/","dgPassFrontmatter":true}
---

# æ–‡çŒ®ä¿¡æ¯
## DOI
10.1002/jts.22239

## æ ‡é¢˜
A Functional Near-Infrared Spectroscopy Study of Trauma-Related Auditory and Olfactory Cues: Posttraumatic Stress Disorder or Combat Experience?

## ä½œè€…
Michael A. Gramlich, Sandra M. Neer, Deborah C. Beidel, Corey J. Bohil, Clint A. Bowers

## æ—¶é—´
2017-12-01

## æ‘˜è¦
The prevalence of posttraumatic stress disorder (PTSD) among U.S. veterans deployed to Iraq or Afghanistan necessitates the need for comprehensive assessment and treatment strategies. This study investigated the utility of a combat-related PTSD symptom provocation paradigm to elicit unique neurological responses across three groups: combat veterans with PTSD, combat veterans without PTSD, and nonmilitary participants without PTSD. Using functional near-infrared spectroscopy (fNIRS) the results indicated that combat veterans with PTSD demonstrated significant activation to a trauma-related sound compared with nonmilitary personnel, channel 14: d = 1.03, 95% confidence interval (CI) [0.28, 1.76]; channel 15: d = 1.30, 95% CI [0.53, 2.06]; and combat veterans without PTSD, channel 14: d = 0.87, 95% CI [0.14, 1.59]. Specifically, this increased neural activation was approximately located in the right medial superior prefrontal cortex (Brodmann areas 9/10), an area associated with experiencing negative or threatening stimuli and emotional detachment. There were no differences across the groups for nontrauma-related sounds. Results were less clear with respect to a combat-related odor. These results suggest a specific neurophysiological response to trauma-related cues and, if replicated, may offer a biomarker for combat-related PTSD. Such a response could provide incremental validity over diagnostic assessments alone and assist in planning and monitoring of treatment outcome.

# æ³¨é‡Š

## é‡è¡¨ï¼šCAPS
æˆ‘ä»¬ä½¿ç”¨ä¸´åºŠåŒ»ç”Ÿç®¡ç†çš„ PTSD é‡è¡¨ï¼ˆCAPSï¼›Blake ç­‰ï¼Œ1995ï¼‰ç­›é€‰ PTSDã€‚ CAPS å…·æœ‰è‰¯å¥½çš„å†…éƒ¨ä¸€è‡´æ€§ï¼ˆCronbach's Î± = 0.80 è‡³ 0.90ï¼‰ã€è¾ƒå¼ºçš„æ”¶æ•›æ•ˆåº¦ï¼ˆr = 0.70 è‡³ 0.90ï¼‰ä»¥åŠçµæ•åº¦å’Œç‰¹å¼‚æ€§å€¼é€šå¸¸åˆ†åˆ«é«˜äº 0.80 å’Œ 0.90ï¼ˆWeathersã€Keane å’Œæˆ´ç»´æ£®ï¼Œ2001ï¼‰ã€‚æœ¬ç ”ç©¶å‘ç°çš„ CAPS çš„å†…éƒ¨ä¸€è‡´æ€§æ˜¯å¯ä»¥æ¥å—çš„ï¼ˆCVï¼šCronbachâ€™s Î± = .72ï¼›PTSD+ï¼šCronbachâ€™s Î± = .93ï¼‰ã€‚
## è¿‘çº¢å¤–æ•°æ®é‡‡é›†
NIRSport-88 æ˜¯ä¸€æ¬¾å¤šé€šé“ç§»åŠ¨ fNIRS è®¾å¤‡ï¼ˆNIRx Medical Technologies, LLCï¼ŒæŸæ—ï¼Œå¾·å›½ï¼‰ï¼Œå¯æµ‹é‡å—…è§‰å’Œå¬è§‰ä»»åŠ¡æœŸé—´å«æ°§å’Œè„±æ°§è¡€çº¢è›‹ç™½æµ“åº¦çš„å˜åŒ–ã€‚è¯¥ç³»ç»Ÿé‡‡ç”¨ 8 æº/8 æ¢æµ‹å™¨é…ç½®ï¼Œå…·æœ‰ 22 ä¸ªæ•°æ®é€šé“ï¼Œè¦†ç›–å·¦å³ PFC åŠçƒï¼ˆå¦‚å›¾ 1 æ‰€ç¤ºï¼‰ã€‚æµ‹é‡æ•°æ®é€šé“å¤„æ¯ä¸ªæº-æ¢æµ‹å™¨ä¹‹é—´çš„è·ç¦»çº¦ä¸º 3 cmã€‚é€šé“ä½ç½®åŸºäºè„‘ç”µå›¾ (EEG) æ•°æ®æ”¶é›†ä¸­å¸¸ç”¨çš„å›½é™… 10-20 ç³»ç»Ÿã€‚ç”±äºå¤§è„‘ç»“æ„çš„ä¸ªä½“å·®å¼‚ä»¥åŠæœ¬ç ”ç©¶ç¼ºä¹è§£å‰–ç£å…±æŒ¯æˆåƒè„‘æ‰«æï¼Œå¸ƒç½—å¾·æ›¼åŒº (BA) çš„å®šä½æ˜¯è¿‘ä¼¼çš„ã€‚æˆ‘ä»¬ä½¿ç”¨ NIRS é‡‡é›†è½¯ä»¶ï¼ˆNIRStarï¼›2014 å¹´å‘å¸ƒï¼ŒNIRx Medical Technologies, LLCï¼Œæ ¼ä¼¦é»‘å¾·ï¼Œçº½çº¦å·ï¼Œç¾å›½ï¼‰è¿›è¡Œæ•°æ®æ”¶é›†ã€‚
## è¿‘çº¢å¤–æ•°æ®å¤„ç†
æœ€åˆï¼Œå°–å³°ä¼ªå½±å’Œä¸è¿ç»­æ€§è¢«è‡ªåŠ¨æ£€æµ‹å’Œæ¶ˆé™¤ã€‚ç›¸é‚»æ•°æ®ç‚¹ä¹‹é—´çš„å˜åŒ–å¤§äºæ¯ä¸ªé€šé“æ—¶é—´è¿‡ç¨‹å¹³å‡å€¼çš„äº”ä¸ªæ ‡å‡†å·®è¢«è®¤ä¸ºæ˜¯äººä¸ºå› ç´ ã€‚æ¥ä¸‹æ¥çš„æ•°æ®ç»è¿‡å¸¦é€šæ»¤æ³¢ï¼Œä»¥æ¶ˆé™¤ç¼“æ…¢çš„æ•°æ®æ¼‚ç§»ï¼ˆä½æˆªæ­¢é¢‘ç‡ = 0.01Hzï¼‰å’Œé«˜é¢‘å™ªå£°ï¼ˆé«˜æˆªæ­¢é¢‘ç‡ = 0.2Hzï¼‰ã€‚



